Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by Geir Olav Hjortland
Based on 3 articles published since 2010
(Why 3 articles?)
||||

Between 2010 and 2020, G. O. Hjortland wrote the following 3 articles about Pancreatic Neoplasms.
 
+ Citations + Abstracts
1 Article Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3). 2018

Ali, Abir Salwa / Grönberg, Malin / Langer, Seppo W / Ladekarl, Morten / Hjortland, Geir Olav / Vestermark, Lene Weber / Österlund, Pia / Welin, Staffan / Grønbæk, Henning / Knigge, Ulrich / Sorbye, Halfdan / Janson, Eva Tiensuu. ·Department of Medical Sciences, Section of Endocrine Oncology, Uppsala University, Uppsala, Sweden. abir.ali@medsci.uu.se. · Department of Medical Sciences, Section of Endocrine Oncology, Uppsala University, Uppsala, Sweden. · Departments of Surgery C and Endocrinology PE, Rigshospitalet, Faculty of Health Science, University of Copenhagen, Copenhagen, Denmark. · Department of Oncology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark. · Department of Oncology, Aarhus University Hospital, Aarhus, Denmark. · Department of Oncology, Oslo University Hospital, Oslo, Norway. · Department of Oncology, Odense University Hospital, Odense, Denmark. · Department of Oncology, Tampere University Hospital and Tampere University, Tampere, Finland. · Department of Oncology, Helsinki University Hospital and Helsinki University, Helsinki, Finland. · Departments of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark. · Department of Oncology, Haukeland University Hospital, Bergen, Norway. ·Med Oncol · Pubmed #29511910.

ABSTRACT: High-grade gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs, G3) are aggressive cancers of the digestive system with poor prognosis and survival. Platinum-based chemotherapy (cisplatin/carboplatin + etoposide) is considered the first-line palliative treatment. Etoposide is frequently administered intravenously; however, oral etoposide may be used as an alternative. Concerns for oral etoposide include decreased bioavailability, inter- and intra-patient variability and patient compliance. We aimed to evaluate possible differences in progression-free survival (PFS) and overall survival (OS) in patients treated with oral etoposide compared to etoposide given as infusion. Patients (n = 236) from the Nordic NEC study were divided into three groups receiving etoposide as a long infusion (24 h, n = 170), short infusion (≤ 5 h, n = 33) or oral etoposide (n = 33) according to hospital tradition. PFS and OS were analyzed with Kaplan-Meier (log-rank), cox proportional hazard ratios and confidence intervals. No statistical differences were observed in PFS or OS when comparing patients receiving long infusion (median PFS 3.8 months, median OS 14.5 months), short infusion (PFS 5.6 months, OS 11.0 months) or oral etoposide (PFS 5.4 months, OS 11.3 months). We observed equal efficacy for the three administration routes suggesting oral etoposide may be safe and efficient in treating high-grade GEP-NEN, G3 patients scheduled for cisplatin/carboplatin + etoposide therapy.

2 Article Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma. 2017

Ali, Abir Salwa / Grönberg, Malin / Federspiel, Birgitte / Scoazec, Jean-Yves / Hjortland, Geir Olav / Grønbæk, Henning / Ladekarl, Morten / Langer, Seppo W / Welin, Staffan / Vestermark, Lene Weber / Arola, Johanna / Österlund, Pia / Knigge, Ulrich / Sorbye, Halfdan / Grimelius, Lars / Janson, Eva Tiensuu. ·Department of Medical Sciences, Section of Endocrine Oncology, Uppsala University, Uppsala, Sweden. · Department of Pathology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark. · Department of Biopathology, Institut Gustave Roussy, Villejuif, France. · Department of Oncology, Oslo University, Oslo, Norway. · Department of Hepatology & Gastroenterology, Aarhus university Hospital, Aarhus, Denmark. · Department of Oncology, Aarhus University Hospital, Aarhus, Denmark. · Department of Oncology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark. · Department of Oncology, Odense University Hospital, Odense, Denmark. · Pathology, HUSLAB, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. · Department of Oncology, Helsinki University Hospital and Helsinki University, Helsinki Finland. · Department of Oncology, Tampere University Hospital, Tampere, Finland. · Department of Surgery C and Endocrinology PE, Rigshospitalet, Faculty of Health Science, University of Copenhagen, Copenhagen, Denmark. · Department of Oncology, Haukeland University Hospital and Department of Clinical Science, University of Bergen, Bergen, Norway. · Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden. ·PLoS One · Pubmed #29112960.

ABSTRACT: BACKGROUND: Gastroenteropancreatic neuroendocrine carcinomas (GEP-NECs) are aggressive, rapidly proliferating tumors. Therapeutic response to current chemotherapy regimens is usually short lasting. The aim of this study was to examine the expression and potential clinical importance of immunoreactive p53 protein in GEP-NEC. MATERIALS AND METHODS: Tumor tissues from 124 GEP-NEC patients with locally advanced or metastatic disease treated with platinum-based chemotherapy were collected from Nordic centers and clinical data were obtained from the Nordic NEC register. Tumor proliferation rate and differentiation were re-evaluated. All specimens were immunostained for p53 protein using a commercially available monoclonal antibody. Kaplan-Meier curves and cox regression analyses were used to assess progression-free survival (PFS) and overall survival (OS). RESULTS: All tumor tissues were immunoreactive for either one or both neuroendocrine biomarkers (chromogranin A and synaptophysin) and Ki67 index was >20% in all cases. p53 immunoreactivity was only shown in 39% of the cases and was not found to be a prognostic marker for the whole cohort. However, p53 immunoreactivity was correlated with shorter PFS in patients with colorectal tumors (HR = 2.1, p = 0.03) in a univariate analysis as well as to poorer PFS (HR = 2.6, p = 0.03) and OS (HR = 3.4, p = 0.02) in patients with colorectal tumors with distant metastases, a correlation which remained significant in the multivariate analyses. CONCLUSION: In this cohort of GEP-NEC patients, p53 expression could not be correlated with clinical outcome. However, in patients with colorectal NECs, p53 expression was correlated with shorter PFS and OS. Further studies are needed to establish the role of immunoreactive p53 as a prognostic marker for GEP-NEC patients.

3 Article Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas. 2017

Galleberg, R B / Knigge, U / Tiensuu Janson, E / Vestermark, L W / Haugvik, S-P / Ladekarl, M / Langer, S W / Grønbæk, H / Österlund, P / Hjortland, G O / Assmus, J / Tang, L / Perren, A / Sorbye, H. ·Department of Oncology, Haukeland University Hospital, Bergen, Norway. Electronic address: renate.berget.galleberg@helse-bergen.no. · Departments of Surgery C and Endocrinology PE, Rigshospitalet, University of Copenhagen, Denmark. Electronic address: rxs484@ku.dk. · Department of Medical Sciences, Uppsala University, Sweden. Electronic address: eva.tiensuu_janson@medsci.uu.se. · Department of Oncology, Odense University Hospital, Denmark. Electronic address: lene.vestermark@syd.dk. · Department of Hepato-Pancreato-Biliary Surgery, Rikshospitalet, Oslo University Hospital, Norway. Electronic address: sphaugvik@yahoo.de. · Department of Oncology, Aarhus University Hospital, Denmark. Electronic address: mortlade@rm.dk. · Department of Oncology, Rigshospitalet, University of Copenhagen, Denmark. Electronic address: swlanger@dadlnet.dk. · Department of Hepatology and Gastroenterology, Aarhus University Hospital, Denmark. Electronic address: henning.gronbaek@aarhus.rm.dk. · Department of Oncology, Helsinki University Central Hospital, Finland. Electronic address: pia.osterlund@pshp.fi. · Department of Oncology, Oslo University Hospital, Norway. Electronic address: goo@ous-hf.no. · Center for Clinical Research, Haukeland University Hospital, Bergen, Norway. Electronic address: jorg.assmus@helse-bergen.no. · Department of Pathology, MSKCC, New York, USA. Electronic address: tangl@MSKCC.ORG. · Department of Pathology, University of Bern, Switzerland. Electronic address: aurel.perren@pathology.unibe.ch. · Department of Oncology, Haukeland University Hospital, Bergen, Norway; Department of Clinical Science, University of Bergen, Norway. Electronic address: Halfdan.sorbye@helse-bergen.no. ·Eur J Surg Oncol · Pubmed #28522174.

ABSTRACT: BACKGROUND: Gastroenteropancreatic neuroendocrine carcinomas (GEP-NEC) are generally characterized by synchronous metastases, high aggressiveness and a dismal prognosis. Current international guidelines do not recommend surgical treatment of liver metastases, however the existing data are scarce. The aim of this study was to evaluate the results of curatively intended resection/radiofrequency ablation (RFA) of liver metastases in patients with metastatic GEP-NEC. METHODS: 32 patients with a diagnosis of high-grade gastroenteropancreatic neuroendocrine neoplasm (Ki-67 > 20%) and with intended curative resection/RFA of liver metastases, were identified among 840 patients from two Nordic GEP-NEC registries. Tumor morphology (well vs poor differentiation) was reassessed. Overall survival (OS) and progression-free survival (PFS) was assessed by Kaplan-Meier analyses for the entire cohort and for subgroups. RESULTS: Median OS after resection/RFA of liver metastases was 35.9 months (95%-CI: 20.6-51.3) with a five-year OS of 43%. The median PFS was 8.4 months (95%-CI: 3.9-13). Four patients (13%) were disease-free after 5 years. Two patients had well-differentiated morphology (NET G3) and 20 patients (63%) had Ki-67 ≥ 55%. A Ki-67 < 55% and receiving adjuvant chemotherapy were statistically significant factors of improved OS after liver resection/RFA. CONCLUSION: This study shows a long median and long term survival after liver surgery/RFA for these selected metastatic GEP-NEC patients, particularly for the group with a Ki-67 in the relatively lower G3 range. Our findings indicate a possible role for surgical treatment of liver metastases in the management of this patient population.